NANOVIRICIDES, INC.

Form 4 May 12, 2015

# FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL OMB** 

3235-0287 Number: January 31, Expires:

2005 Estimated average

burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* **BONIUK MILTON** 

2. Issuer Name and Ticker or Trading Symbol

NANOVIRICIDES, INC. [NNVC]

5. Relationship of Reporting Person(s) to

Issuer

(Last)

(First) (Middle) 3. Date of Earliest Transaction

(Month/Day/Year)

(Check all applicable)

C/O NANOVIRICIDES, INC., 135 **WOOD STREET, SUITE 205** 

> (Street) 4. If Amendment, Date Original

> > Filed(Month/Day/Year)

03/06/2015

\_X\_\_ Director 10% Owner Other (specify Officer (give title below)

6. Individual or Joint/Group Filing(Check Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

WEST HAVEN, CT 06516

(City) (State)			(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
	1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5)  (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
	Common Stock, par	03/06/2015		Code V	Amount 190,477	(D)	Price \$	(Instr. 3 and 4) 942,859 (1)	I	Boniuk	
	value \$0.001				,		2.63	, <u> </u>		Interest, Ltd	
	Common Stock, par value \$0.001	03/06/2015		P	190,477	A	\$ 2.63	571,431 (2)	I	Boniuk Charitable Foundation	
	Common Stock, par value \$0.001	05/08/2015		P	25,000	A	\$ 1.75	1,455,391 (3)	D		

#### Edgar Filing: NANOVIRICIDES, INC. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 9. Nu Deriv Secur Bene Own Follo Repo Trans

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerci	isable and	7. Titl	e and	8. Price of	9
	Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Date, if TransactionNumber		Expiration Date Ame		Amou	nt of	Derivative	J
	Security	or Exercise		any	Code	of	(Month/Day/Y	(ear)	Under	lying	Security	,
	(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative			Securities	(Instr. 5)	]	
		Derivative			Securities				(Instr.	3 and 4)		(
		Security				Acquired						J
						(A) or						J
						Disposed						-
						of (D)						(
						(Instr. 3,						
						4, and 5)						
										Amount		
							Date Exercisable	* ']'	Title	or Number		
					Code V	(A) (D)				of Charac		
					Code V	(A) (D)				Shares		

# **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

BONIUK MILTON C/O NANOVIRICIDES, INC. 135 WOOD STREET, SUITE 205 WEST HAVEN, CT 06516

X

## **Signatures**

/s/ Milton Boniuk 05/12/2015

\*\*Signature of Date
Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations, See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Does not include: warrants to purchase an additional 285,714 shares of common stock or an indeterminate number of shares of common stock issuable upon conversion of debentures held by Boniuk Interests, Ltd.; 758,963 shares of common stock and warrants to purchase an additional 571,428 shares of common stock held by Milton Boniuk and his wife; 380,954 shares of common stock held by the Boniuk Charitable Foundation; or 952,381 shares of common stock issuable upon conversion of a 10% Coupon Series C Convertible Debenture or 187,000 shares of Series A Preferred Stock held by Milton Boniuk IRA. Dr. Milton Boniuk, a member of the Company's Board of Directors, holds voting and dispositive power over Boniuk Interests, Ltd., the Boniuk Charitable Foundation, and the Milton Boniuk IRA.

**(2)** 

Reporting Owners 2

#### Edgar Filing: NANOVIRICIDES, INC. - Form 4

Does not include an indeterminate number of shares of common stock issuable upon conversion of debentures held by Boniuk Charitable Foundation or other securities of the Registrant held by the Reporting Person set forth in Note 1. Dr. Milton Boniuk, a member of the Company's Board of Directors, holds voting and dispositive power over Boniuk Charitable Foundation.

- Includes 883,963 shares of Common Stock and warrants to purchase an additional 571,428 shares of Common Stock held by the Reporting Person and his wife. Does not include: 942,859 shares of Common Stock, warrants to purchase an additional 285,714 shares of Common Stock or an indeterminate number of shares of Common Stock issuable upon conversion of debentures held by Boniuk Interests,
- (3) Ltd.; 571,431 shares of Common Stock held by the Boniuk Charitable Foundation; or 952,381 shares of Common Stock issuable upon conversion of a 10% Coupon Series C Convertible Debenture or 187,000 shares of Series A Preferred Stock held by Milton Boniuk IRA, convertible into 654,500 shares of common stock, which are not readily convertible. Dr. Boniuk holds voting and dispositive power over the Boniuk Charitable Foundation, Boniuk Interests Ltd. and the Milton Boniuk IRA.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.